

# Alessandro Mantovani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5875367/publications.pdf>

Version: 2024-02-01

167  
papers

7,094  
citations

66234

42  
h-index

69108

77  
g-index

168  
all docs

168  
docs citations

168  
times ranked

8047  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?. <i>Journal of Hepatology</i> , 2018, 68, 335-352.	1.8	495
2	Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. <i>Diabetes Care</i> , 2018, 41, 372-382.	4.3	407
3	Complications, morbidity and mortality of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154170.	1.5	278
4	Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2018, 79, 64-76.	1.5	261
5	Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. <i>Gut</i> , 2021, 70, 962-969.	6.1	238
6	Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 903-913.	3.7	227
7	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 425-439.	8.2	207
8	Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1236-1248.	1.1	196
9	Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. <i>Gut</i> , 2020, 69, 1545-1547.	6.1	166
10	Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. <i>Gut</i> , 2022, 71, 156-162.	6.1	162
11	Coronavirus disease 2019 (COVID-19) in children and/or adolescents: a meta-analysis. <i>Pediatric Research</i> , 2021, 89, 733-737.	1.1	156
12	Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. <i>Metabolites</i> , 2021, 11, 73.	1.3	145
13	Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. <i>Gut</i> , 2022, 71, 778-788.	6.1	132
14	Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis. <i>Liver International</i> , 2020, 40, 1316-1320.	1.9	131
15	Nonalcoholic Fatty Liver Disease Is Independently Associated With an Increased Incidence of Chronic Kidney Disease in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2014, 37, 1729-1736.	4.3	129
16	Patients with diabetes are at higher risk for severe illness from COVID-19. <i>Diabetes and Metabolism</i> , 2020, 46, 335-337.	1.4	124
17	Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. <i>Annals of Translational Medicine</i> , 2017, 5, 270-270.	0.7	109
18	Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with Type 2 diabetes. <i>Clinical Science</i> , 2013, 125, 301-310.	1.8	107

#	ARTICLE	IF	CITATIONS
19	Treatments for NAFLD: State of Art. International Journal of Molecular Sciences, 2021, 22, 2350.	1.8	102
20	Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2016, 61, 1246-1267.	1.1	99
21	Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring. Diabetes Care, 2016, 39, 1416-1423.	4.3	95
22	Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. The Lancet Gastroenterology and Hepatology, 2022, 7, 367-378.	3.7	92
23	Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Thyroid, 2018, 28, 1270-1284.	2.4	87
24	Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2015, 64, 879-887.	1.5	82
25	Prognostic Impact of Diabetes on Long-term Survival Outcomes in Patients With Heart Failure: A Meta-analysis. Diabetes Care, 2017, 40, 1597-1605.	4.3	82
26	Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. PLoS ONE, 2015, 10, e0135329.	1.1	81
27	Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes and Metabolism, 2020, 46, 427-441.	1.4	81
28	Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Annals of Hepatology, 2020, 19, 359-366.	0.6	81
29	Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. Metabolism: Clinical and Experimental, 2018, 87, 1-12.	1.5	80
30	NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. International Journal of Molecular Sciences, 2019, 20, 2841.	1.8	79
31	Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 663-669.	1.1	77
32	Association between nonalcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. Liver International, 2019, 39, 758-769.	1.9	75
33	Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. International Journal of Molecular Sciences, 2016, 17, 217.	1.8	73
34	Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites, 2021, 11, 22.	1.3	72
35	Liver fibrosis by FibroScan <sup>®</sup> independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. Liver International, 2020, 40, 347-354.	1.9	59
36	Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics, 2021, 11, 98.	1.3	59

#	ARTICLE	IF	CITATIONS
37	Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. <i>International Journal of Cardiology</i> , 2016, 225, 387-391.	0.8	56
38	Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 215-218.	1.8	54
39	Ceramides and risk of major adverse cardiovascular events: A meta-analysis of longitudinal studies. <i>Journal of Clinical Lipidology</i> , 2020, 14, 176-185.	0.6	51
40	Nonalcoholic Fatty Liver Disease Is Associated with Aortic Valve Sclerosis in Patients with Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2014, 9, e88371.	1.1	49
41	Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1021-1026.	1.2	47
42	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 351-367.	1.4	47
43	Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2019, 45, 347-355.	1.4	47
44	Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 296-303.	1.4	47
45	Nonalcoholic Fatty Liver Disease (NAFLD) and Risk of Cardiac Arrhythmias: A New Aspect of the Liver-heart Axis. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, 1-8.	0.7	47
46	Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of the American College of Cardiology</i> , 2022, 79, 180-191.	1.2	46
47	Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 375-388.	1.9	45
48	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. <i>Metabolism: Clinical and Experimental</i> , 2020, 113, 154413.	1.5	45
49	Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD. <i>Hepatology</i> , 2019, 70, 142-153.	3.6	44
50	Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?. <i>Digestive and Liver Disease</i> , 2019, 51, 462-470.	0.4	44
51	Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. <i>PLoS ONE</i> , 2017, 12, e0185459.	1.1	42
52	Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. <i>International Journal of Cardiology</i> , 2018, 265, 162-168.	0.8	41
53	Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 802-810.	1.8	39
54	Association between <i>Helicobacter pylori</i> infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 56-65.	1.5	38

#	ARTICLE	IF	CITATIONS
55	Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. <i>PLoS ONE</i> , 2017, 12, e0173398.	1.1	38
56	Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. <i>Diabetes and Metabolism</i> , 2019, 45, 480-487.	1.4	36
57	Coronavirus disease 2019 (COVID-19): we don't leave women alone. <i>International Journal of Public Health</i> , 2020, 65, 235-236.	1.0	36
58	Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. <i>Digestive and Liver Disease</i> , 2019, 51, 1586-1592.	0.4	34
59	Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. <i>Diabetes and Metabolism</i> , 2020, 46, 505-507.	1.4	34
60	PNPLA3 rs1148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings. <i>Liver International</i> , 2020, 40, 1130-1141.	1.9	33
61	PNPLA3 gene and kidney disease. <i>Diabetes and Metabolism</i> , 2020, 46, 42-50.		32
62	Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza) Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e01152.	1.5	30
63	Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis. <i>Hepatology</i> , 2019, 70, 812-823.	3.6	30
64	Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. <i>Future Medicinal Chemistry</i> , 2019, 11, 2171-2192.	1.1	30
65	Nonalcoholic Fatty Liver Disease and Reduced Serum Vitamin D <sub>3</sub> Levels. <i>Metabolic Syndrome and Related Disorders</i> , 2013, 11, 217-228.	0.5	29
66	Association of Plasma Ceramides With Myocardial Perfusion in Patients With Coronary Artery Disease Undergoing Stress Myocardial Perfusion Scintigraphy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2854-2861.	1.1	29
67	Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography. <i>Diabetes and Metabolism</i> , 2020, 46, 150-157.	1.4	29
68	Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 159-167.	1.8	28
69	Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease. <i>Diabetes and Metabolism</i> , 2021, 47, 101152.	1.4	28
70	Plasma Bile Acid Profile in Patients with and without Type 2 Diabetes. <i>Metabolites</i> , 2021, 11, 453.	1.3	28
71	Comparison of Two Creatinine-Based Estimating Equations in Predicting All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2347-2353.	4.3	26
72	Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1277-1288.	1.8	26

#	ARTICLE	IF	CITATIONS
73	Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis. <i>Diabetes and Metabolism</i> , 2019, 45, 536-544.	1.4	25
74	Early impairment in left ventricular longitudinal systolic function is associated with an increased risk of incident atrial fibrillation in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 413-418.	1.2	24
75	Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 2317-2329.	1.9	24
76	Multiple Evanescent White Dot Syndrome: A Multimodal Imaging Study of Foveal Granularity. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 141-147.	1.0	23
77	Advances and potential new developments in imaging techniques for posterior uveitis Part 2: invasive imaging methods. <i>Eye</i> , 2021, 35, 52-73.	1.1	23
78	Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2022, 11, 968.	1.0	20
79	MAFLD vs NAFLD: Where are we?. <i>Digestive and Liver Disease</i> , 2021, 53, 1368-1372.	0.4	19
80	Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. <i>Nature Reviews Endocrinology</i> , 2022, 18, 638-650.	4.3	18
81	Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 223-231.	1.8	17
82	Gender disparity in editorial boards of journals in neurology. <i>Neurology</i> , 2020, 95, 489-491.	1.5	17
83	NAFLD, MAFLD and DAFLD. <i>Digestive and Liver Disease</i> , 2020, 52, 1519-1520.	0.4	16
84	Hypothyroidism and nonalcoholic fatty liver disease – a chance association?. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.3	15
85	Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy. <i>Metabolism: Clinical and Experimental</i> , 2018, 85, 305-312.	1.5	15
86	Association between MBOAT7 rs641738 polymorphism and non-alcoholic fatty liver in overweight or obese children. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1548-1555.	1.1	14
87	Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes – The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 3464-3473.	1.1	14
88	Sural nerve biopsy: current role and comparison with serum neurofilament light chain levels. <i>Journal of Neurology</i> , 2020, 267, 2881-2887.	1.8	13
89	Relationship between increased left atrial volume and microvascular complications in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 822-828.	1.2	12
90	Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSI-HF trial. <i>ESC Heart Failure</i> , 2020, 7, 3288-3297.	1.4	12

#	ARTICLE	IF	CITATIONS
91	Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Type 2 Diabetes: A New Imaging Possibility and a New Biomarker. <i>Calcified Tissue International</i> , 2021, 108, 231-239.	1.5	12
92	Risk of Kidney Dysfunction IN Nafld. <i>Current Pharmaceutical Design</i> , 2020, 26, 1045-1061.	0.9	12
93	Association between subclinical left ventricular systolic dysfunction and glycemic control in asymptomatic type 2 diabetic patients with preserved left ventricular function. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1035-1040.	1.2	11
94	NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107684.	1.2	11
95	Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies. , 0, , .		11
96	MAFLD and CKD: An Updated Narrative Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7007.	1.8	11
97	Relation of elevated serum uric acid levels to first-degree heart block and other cardiac conduction defects in hospitalized patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1691-1697.	1.2	10
98	The E/e <sup>2</sup> ™ ratio difference between subjects with type 2 diabetes and controls. A meta-analysis of clinical studies. <i>PLoS ONE</i> , 2018, 13, e0209794.	1.1	10
99	Gender difference in authorship of clinical practice guidelines and position statements in endocrinology. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 489-490.	1.8	10
100	A call to action for fatty liver disease. <i>Liver International</i> , 2021, 41, 1182-1185.	1.9	10
101	Looking for women in hepatology: Sex authorship differences in clinical practice guidelines and position statements. <i>Digestive and Liver Disease</i> , 2019, 51, 911-913.	0.4	9
102	Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 326-330.	1.4	9
103	Severe hypoglycemia in patients with known diabetes requiring emergency department care: A report from an Italian multicenter study. <i>Journal of Clinical and Translational Endocrinology</i> , 2016, 5, 46-52.	1.0	8
104	Gender disparity in authorships of manuscripts on the COVID-19 outbreak. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2022, 30, 523-524.	0.8	8
105	Honey dressing on a leg ulcer with tendon exposure in a patient with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.2	7
106	Increased aortic stiffness index in patients with type 1 diabetes without cardiovascular disease compared to controls. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 1109-1115.	1.8	5
107	Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 527-547.	1.0	5
108	Association between lower plasma adiponectin levels and higher plasma thrombin generation parameters in men with type 2 diabetes: role of plasma triglycerides. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 547-555.	1.8	5



#	ARTICLE	IF	CITATIONS
109	Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 518-521.	0.7	5
110	Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study. <i>Hormones</i> , 2022, 21, 477-486.	0.9	5
111	NAFLD and risk of cardiac arrhythmias: Is hyperuricemia a neglected pathogenic mechanism?. <i>Digestive and Liver Disease</i> , 2018, 50, 518-520.	0.4	4
112	Thyroid Dysfunction and Nonalcoholic Fatty Liver Disease: We Need New Larger and Well-Designed Longitudinal Studies. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1970-1976.	1.1	4
113	Pressure heel ulcers in patients with type 2 diabetes: Is it T.I.M.E. to customise wound bed preparation according to different heel areas?. <i>International Wound Journal</i> , 2018, 15, 849-850.	1.3	4
114	Is it time to include non-alcoholic fatty liver disease in the current risk scores for atrial fibrillation?. <i>Digestive and Liver Disease</i> , 2018, 50, 626-628.	0.4	4
115	Left ventricular chamber dilation and filling pressure may help to categorise patients with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000529.	1.2	4
116	Time to revise the definition of NAFLD: A purist vision. <i>Digestive and Liver Disease</i> , 2019, 51, 457-458.	0.4	4
117	Assessment of simple strategies for identifying undiagnosed diabetes and prediabetes in the general population. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 75-81.	1.8	4
118	Pulmonary Fat Embolism and Coronary Amyloidosis. <i>American Journal of Case Reports</i> , 2018, 19, 744-747.	0.3	4
119	Plasma trans-fatty acid and risk of nonalcoholic fatty liver disease: New data from National Health and Nutrition Examination Survey (NHANES). <i>International Journal of Cardiology</i> , 2018, 272, 329-330.	0.8	3
120	Not all NAFLD patients are the same: We need to find a personalized therapeutic approach. <i>Digestive and Liver Disease</i> , 2019, 51, 176-177.	0.4	3
121	Type 2 Diabetes, sarcopenic obesity and Mediterranean food pattern: Considerations about the therapeutic effect and the problem of maintaining weight loss and healthy habits. The outpatient experience of two clinical cases. <i>Journal of Clinical and Translational Endocrinology: Case Reports</i> , 2020, 16, 100061.	0.4	3
122	Scientific productivity in neurology: impact of the socio-economic status. <i>Neurological Sciences</i> , 2021, 42, 1563-1566.	0.9	3
123	Diabetic foot complicated by vertebral osteomyelitis and epidural abscess. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, 150132.	0.2	3
124	GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis. <i>Exploration of Medicine</i> , 2020, 1, 108-123.	1.5	3
125	Association between higher serum uric acid levels and plasma N-terminal pro-B-type natriuretic peptide concentrations in patients with coronary artery disease and without overt heart failure. <i>International Journal of Cardiology</i> , 2022, , .	0.8	3
126	Hepatitis C virus infection and diabetes: a complex bidirectional relationship. <i>Diabetes Research and Clinical Practice</i> , 2022, , 109870.	1.1	3



#	ARTICLE	IF	CITATIONS
127	Association between decreasing estimated glomerular filtration rate and risk of cardiac conduction defects in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2018, 44, 473-481.	1.4	2
128	Increased aortic stiffness in adults with chronic indeterminate Chagas disease. <i>PLoS ONE</i> , 2019, 14, e0220689.	1.1	2
129	The dawn of a new era for nonalcoholic fatty liver disease?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 629-631.	0.7	2
130	Gender disparity in editorial boards of scientific journals in endocrinology. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 549-550.	1.8	2
131	GLP-1 receptor agonists and reduction of liver fat content in NAFLD patients: Just a question of weight loss?. <i>Digestive and Liver Disease</i> , 2021, 53, 1673-1674.	0.4	2
132	Breastfeeding duration and reduced risk of NAFLD in midlife of parous women. <i>Exploration of Medicine</i> , 0, , .	1.5	2
133	Cutaneous squamous carcinoma in a patient with diabetic foot: an unusual evolution of a frequent complication. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.2	2
134	Prevalence and incidence of intra- and extrahepatic complications of NAFLD in patients with type 2 diabetes mellitus. <i>Hepatoma Research</i> , 0, 2020, .	0.6	2
135	Recent Developments in NAFLD. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2882.	1.8	2
136	Editorial: higher levels of certain serum bile acids in nonalcoholic fatty liver disease—new insights from Guatemala. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 357-360.	1.9	2
137	SAT-314-Liver fibrosis by FibroScan is highly prevalent in type 2 diabetic patients with NAFLD and fairly normal liver enzymes but increased uric acid. <i>Journal of Hepatology</i> , 2019, 70, e777-e778.	1.8	1
138	Nonalcoholic Fatty Liver Disease and Bone Mineral Density in Children and Adolescents: Specific Considerations for Future Studies. <i>Digestive Diseases and Sciences</i> , 2019, 64, 898-900.	1.1	1
139	Causality between nonalcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes. <i>Liver International</i> , 2019, 39, 779-779.	1.9	1
140	Letter to the Editor about PNPLA3 gene polymorphism in Brazilian patients with type 2 diabetes: A prognostic marker beyond liver disease?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 162-163.	1.1	1
141	Gender differences in editorial boards of journals in hepatology. <i>Digestive and Liver Disease</i> , 2020, 52, 469-470.	0.4	1
142	Primary cutaneous B-cell lymphoma and chronic leg ulcers in a patient with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2017, 2017, .	0.2	1
143	COVID-19 outbreak in children and/or adolescents. <i>Pediatric Research</i> , 2021, , .	1.1	1
144	Country rankings on the scientific production in endocrinology and diabetology. <i>Exploration of Medicine</i> , 2020, 1, .	1.5	1

#	ARTICLE	IF	CITATIONS
145	Glucose-lowering agents and reduced risk of incident non-alcoholic fatty liver disease: new insights. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 156-160.	0.7	1
146	Association between KLF6 rs3750861 polymorphism and plasma ceramide concentrations in post-menopausal women with type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1283-1287.	1.1	1
147	Higher Levels of Plasma Hyaluronic Acid and N-terminal Propeptide of Type III Procollagen Are Associated With Lower Kidney Function in Children With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	1
148	Association between Higher Circulating Leucine-Rich $\alpha$ 2 Glycoprotein 1 Concentrations and Specific Plasma Ceramides in Postmenopausal Women with Type 2 Diabetes. <i>Biomolecules</i> , 2022, 12, 943.	1.8	1
149	Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. <i>Digestive and Liver Disease</i> , 2015, 47, e229.	0.4	0
150	Cardiovascular morbidity and mortality in patients with rheumatic disease: hyperuricemia, a forgotten puzzle piece?. <i>Clinical Rheumatology</i> , 2017, 36, 2869-2870.	1.0	0
151	Diabetes and NAFLD. <i>Endocrinology</i> , 2018, , 1-27.	0.1	0
152	Non-alcoholic fatty liver disease and risk of developing chronic kidney disease: a new piece of a recent puzzle from a large Asian study. <i>AME Medical Journal</i> , 2018, 3, 37-37.	0.4	0
153	Impaired Aortic Valve Growth in Type 1 Diabetes Mellitus. <i>Canadian Journal of Cardiology</i> , 2019, 35, 941.e5-941.e6.	0.8	0
154	THU-323-Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes. <i>Journal of Hepatology</i> , 2019, 70, e302.	1.8	0
155	Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes. <i>Digestive and Liver Disease</i> , 2019, 51, e28-e29.	0.4	0
156	Letter: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density”authors’™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 961-962.	1.9	0
157	Association between increased carotid intima-media thickness and higher serum C-terminal telopeptide of type 1 collagen levels in post-menopausal women with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 409-411.	1.4	0
158	P1737 Echocardiographic estimation of pulmonary artery pressure in young non-complicated patients with type 1 diabetes: results from a single-center observational study. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, .	0.5	0
159	NAFLD fibrosis score identifies not only advanced liver fibrosis but also chronic vascular complications in type 2 diabetic patients. <i>Digestive and Liver Disease</i> , 2020, 52, e45.	0.4	0
160	Diabetes and DAAs. <i>Digestive and Liver Disease</i> , 2020, 52, e23.	0.4	0
161	Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes. Commentary to Sasso and colleagues. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2354-2357.	1.1	0
162	Diabetes and NAFLD. <i>Endocrinology</i> , 2018, , 495-521.	0.1	0

#	ARTICLE	IF	CITATIONS
163	Diabetes and NAFLD. <i>Endocrinology</i> , 2019, , 1-27.	0.1	0
164	Diabetes and NAFLD. <i>Endocrinology</i> , 2020, , 495-521.	0.1	0
165	Echocardiographic parameters according to insulin dose in young patients affected by type 1 diabetes. <i>PLoS ONE</i> , 2020, 15, e0244483.	1.1	0
166	NAFLD, Diabetes, and Other Endocrine Diseases: Clinical Implications. , 2020, , 147-168.		0
167	Estimated peak systolic pulmonary artery pressure in young non-complicated patients with type 1 diabetes. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 5028-5035.	0.5	0